OS

Owen Smith

Director at Vianautis

United Kingdom

Overview 

Owen Smith is a Partner at 4BIO Capital in the United Kingdom, with a strong background in venture capital and strategic planning within the biotechnology sector. Notable highlights of his career include serving as a Director for companies like ViaNautis, Entact Bio, and SparingVision, and his involvement in investments at Series A and Series B stages. Smith's career achievements include investments in key biotechnology companies at critical stages, such as ViaNautis, Entact Bio, and SparingVision, showcasing his expertise in strategic planning and venture capital within the sector. Currently, as a Partner at 4BIO Capital, he plays a significant role in shaping the investment strategies and direction of the firm, leveraging his extensive experience and skills in business continuity and financial reporting.

Work Experience 

4C

4BIO Capital

  • Partner

    2022 - Current

  • Investment Director

    2019 - 2022

    Investments in public and private advanced therapies companies, specialising in biotech investments. Contact: owen@4biocapital.com or op_smith@icloud.com

  • Principal

    2018 - 2019

V

Vianautis

  • Director

    2023

S

SparingVision

  • Director

    2020

    SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing SPVN06, a gene-independent treatment for retinitis pigmentosa, the most common inherited retinal degeneration.

EB

Entact Bio

  • Director

    2019

Entact Bio is a biotechnology company that is in the preclinical stages of developing medications to improve protein function.

Raised $121,321,700.00 from Surveyor Capital, Arkin Bio Ventures, Janus Henderson Investors, Walter and Eliza Hall Institute of Medical Research, Brandon Capital, Abingworth, Qiming Venture Partners USA, venBio Partners, Logos Capital and 4BIO Capital.

entactbio.com

Fulham Supporters Trust

  • Board Member

    2018 - 2024

LT

LogicBio Therapeutics

  • Board Observer

    2017 - 2017

    LogicBio Therapeutics is a gene-therapy company with a mission to develop cures for early-onset life-threatening diseases. The company’s GeneRide technology hitches a therapeutic transgene to a native promoter without disrupting its normal function in the host genome, enabling permanent expression of a functional version of a missing or faulty gene. Thus − with just a single treatment early in a child’s life – LogicBio can potentially deliver a life-long cure for a devastating disease.

D

Depixus

  • Board Observer

    2016 - 2017

    Depixus is developing unique technology to sequence epigenetic modifications to native RNA and DNA at single molecule level.

Arix Bioscience plc

  • Life Sciences VC

    2016 - 2017

    Investment firm focused on early, mid, and late-stage biotech and pharma companies (private and public). Investments involved with: Autolus, Depixus, Verona, OptiKira, LogicBio, Atox Bio

AL

Arthurian Life Sciences

  • Life Sciences VC

    2015 - 2016

    Investments worked on: Cequr, Apitope, Reneuron

GT

Grant Thornton UK LLP

  • Executive

    2013 - 2015

  • Associate

    2010 - 2013

Education 

Investments 

ViaNautis

Series A

Total funding: $25M

Entact Bio

Series A

Total funding: $81M

SparingVision

Series A

Total funding: $130M

Articles About Owen

Relevant Websites